Brendon Stiles: We owe it to our patients with EGFR mutations
Brendon Stiles, Professor and Chief, Thoracic Surgery and Surgical Oncology,
“There are some patients with EGFR mutations who respond to immunotherapy, particularly when combined with chemotherapy or anti-angiogenesis drugs. We owe it to our patients with EGFR mutations to figure out who benefits from these strategies.”
Quoting The Lancet Oncology:
“ICYMI:
Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated tumors non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis.”
Authors: Yi Zhao, Ying He, Wei Wang, Qi Cai, Fan Ge, Zisheng Chen, Jianqi Zheng, Yuan Zhang, Hongsheng Deng, Ying Chen, Shen Lao, Hengrui Liang, Prof Wenhua Liang, MDa, Prof Jianxing He.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023